SMi presents Europe's leading 10th annual conference and exhibition: Pre-Filled Syringes Europe 2018

SMi Group17 - 18 January 2018, London, UK.
Join the calendar event highlight for the medical device industry at Europe's leading 10th annual conference and exhibition on Pre-Filled Syringes when it returns to Central London on 17th and 18th January 2018. Pre-Filled Syringes Europe will once again provide a perfect platform to discuss new advancements and showcase the latest innovations to keep you at the forefront of a dynamic and booming market.

Building on the success of its sell-out global 2017 PFS series of events which saw 100+ attendees join shows in London, Boston and San Diego, the agenda for Pre-Filled Syringes Europe 2018 has been carefully tailored to arm you with the key requirements and tools to adapt to an ever-changing medical landscape in areas that are critical to those working within parenteral drug delivery and injectable devices.

Featured Speakers:

  • Alphons Fakler, Group Head Risk Management, Novartis Pharma
  • Bettine Boltres, Technical Account Manager, West Pharmaceutical Services
  • Elizabeth Baker, Group Manager Licensing Division, MHRA
  • Marcel Mueller, Device Project Leader, Novartis
  • Cedric Gysel, Staff Device Engineer, Janssen
  • Carsten Worsoe, Principal Scientist, CMC Analytical Support, Novo Nordisk
  • Vikas Jaitely, Senior Manager CMC Regulatory Intelligence and Pharmaceutical Science, Merck
  • Susanne Joerg, Head of Formulation Development, Lonza
  • Orla Downes, Head of Business Development Unit, Barts Health Pharmaceuticals
  • Barry Knight, Device Program Lead, UCB Celltech
  • Sudeshna Dutta Ray, Senior Engineer, Advanced Device Technology and Innovation, Amgen
  • Alexander Jung, Senior Manager, Technology and Innovation, Drug Delivery and Devices, Boehringer Ingelheim
  • Christian Dechant, Primary Packaging Director, Boehringer Ingelheim

Sponsors include: Früh Verpackungstechnik Ag, Mitsubishi Gas Chemical, Nemera, Panasonic, West Pharmaceutical Services, Worrell and more

Key Topics for 2018:

  • Engage with the latest regulatory updates and guidelines for ultimate product compliance and efficiency
  • Discuss the emerging hot topic of combination products and benchmark against other industry-leaders
  • Participate in the increased focus towards digital connectivity and smart devices for improved patient adherence
  • Follow approaches to human factors and end-user engagement from formulation to after-market development
  • Witness the latest insights into the broader market trends of increased biologics attention and how to address these challenges head on

This event will sell-out. For further information and to register, please visit:
http://www.pre-filled-syringes.com/wpn

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...